Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease

  title={Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease},
  author={Christos Theleritis and Kostas Siarkos and Everina A Katirtzoglou and Antonios Politis},
  journal={Journal of Geriatric Psychiatry and Neurology},
  pages={26 - 49}
Objective: Apathy is one of the most frequent neuropsychiatric symptoms encountered in Alzheimer disease (AD). Early diagnosis and timely treatment of apathy in AD seem to be of great importance, since apathy has been associated with poor disease outcome, reduced daily functioning, and caregiver distress. Design: Within this context, we conducted an extensive electronic search from the databases included in the National Library of Medicine as well as PsychInfo and Google Scholar for studies… 

Tables from this paper

Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer’s Disease: A Systematic Review

Acetylcholinesterase inhibitors, gingko biloba, and methylphenidate were found to be successful in reducing apathy in patients with AD.

Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders

Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results.

Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials.

  • M. MortbyL. Adler C. Theleritis
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2021

Revisiting Apathy in Alzheimer's Disease: From Conceptualization to Therapeutic Approaches

It is unlikely that a single pharmacological or nonpharmacological strategy will be effective for all cases of apathy in AD, and high-quality evidence research is needed to better understand the role of specific strategies aiming at a personalized approach.

Commentary on Apathy as a Model for Investigating Behavioral and Psychological Symptoms in Dementia

A conceptual framework to guide thinking and research on apathy is described and has clear potential to serve as a much-needed exemplar for advancing a more integrated biopsychosocial research agenda in response to the bioppsychosocial etiology of apathy and, possibly, other BPSDs.

Investigation of Factors Affecting Apathy in Three Major Types of Dementia.

It is demonstrated that apathy is very common symptom in patients with FTD as well as patients with AD and VaD, and health professionals need to be aware of recognize apathy.

The Effectiveness of Non-Pharmacological Interventions on Apathy in Patients With Dementia: A Systematic Review of Systematic Reviews.

Among all the non-pharmacological interventions involved in this review, the effectiveness of multisensory stimulation, music therapy, cognitive stimulation, and pet therapy was relatively robust, and was deemed the most helpful according to evidences available.

Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA

Current literature on the medication management of neuropsychiatric symptoms of dementia in the USA is described and approaches to and concerns about the pharmacological treatment of NPS are highlighted.

Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease

The CSF A β42 concentrations were negatively correlated with apathy scores and patients with severe apathy had significantly lower Aβ42 levels compared to nonapathetic ones, encouraging further studies to untangle the potential association between the complex pathophysiological dynamics of AD and apathy.



Apathy in Neurodegenerative Diseases

Recommendations address clarification of the targeted study population, confounding factors, Mood/cognition, behavior, and treatment, outcome measures, study duration, use of comparators and considerations around environment, and the role of the caregiver and patient assent.

A review of neuroimaging findings of apathy in Alzheimer's disease

Neuroimaging findings lend support to the notion that frontal-subcortical networks are involved in the occurrence of apathy in AD and reveal disease patterns, helping to distinguish clinically distinct cognitive syndromes, and allowing predictions.

Pharmacological Treatment of Apathy in Neurodegenerative Diseases: A Systematic Review

There is as yet insufficient evidence that pharmacological treatment improves apathetic symptoms in patients with neurodegenerative disease, and large-scale, placebo-controlled RCTs with apathy as a primary outcome measure are needed to establish the potential benefit of pharmacological treated apathy.

The Efficacy of Nonpharmacological Treatment for Dementia-related Apathy

A structured, nonpharmacological, short-term occupational therapy intervention is more useful than activities of the patients' own choice for improving apathy in patients with mild or moderate dementia.

Treating Apathy in Alzheimer’s Disease

  • P. BoyleP. Malloy
  • Psychology, Medicine
    Dementia and Geriatric Cognitive Disorders
  • 2003
The assessment and treatment of apathy in AD is reviewed, with emphasis on the utility of acetylcholinesterase inhibitors and the potential benefits of other pharmacologic agents and combined pharmacologic-behavioral interventions.

Pharmacologic treatment of apathy in dementia.

A systematic literature review of studies that used apathy outcome scales to document results of pharmacologic treatments for apathy found limited evidence of efficiency of pharmacotherapy for treatment of apathy in dementia, and recommendations for standardizing research and holistic evaluation and treatment are provided.

Methylphenidate for the Treatment of Apathy in Alzheimer Disease: Prediction of Response Using Dextroamphetamine Challenge

A randomized, double-blind, placebo-controlled crossover trial of methylphenidate in a sample of 13 apathetic AD patients, finding that psychostimulants may be effective in treating features of apathy in AD, and dopaminergic changes may predict response.

Nonpharmacological management of apathy in dementia: a systematic review.

  • H. BrodatyKim Burns
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2012
It is apparent that nonpharmacological interventions have the potential to reduce apathy and that therapeutic activities, particularly those provided individually, have the best available evidence for effectiveness in dementia.

Apathy and agitation: challenges and future directions.

  • C. Lyketsos
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2007
The findings suggest that apathy is closely linked to cognitive impairment and indicate that the emergence of apathy in late life may itself be an indicator of degenerative disease and impending dementia.

Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.

The use of citalopram was associated with greatly reduced irritability without sedation in a group of behaviorally disturbed patients with AD.